Association of Warfarin Therapy with APOE and VKORC1 Genes Polymorphism in Iranian Population

Document Type: Research article

Authors

1 Department of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

4 Department of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

5 Department of Clinical Biochemistry, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

6 Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

7 Cardiovascular Research Center, Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Warfarin is a vitamin K antagonist that genetic and non-genetic factors affected on its dose
requirement in the patients with cardio vascular disease. The aim of this study was whether
the APOE and VKORC1 polymorphisms influence on warfarin dose requirements in the part
of Iranian patients. Blood samples were collected from 86 warfarin-treated patients. After
extraction of genomic DNA, the VKORC1 (rs9923231) and the APOE (rs429358 and rs7412)
polymorphisms were genotyped by PCR-RFLP technique. We found that the Iranian patients
carrying genotypes GA or AA of VKORC1 polymorphism tended to receive lower dose of
warfarin (p = 0.018). Furthermore, the E3/E3 genotype was observed with the frequency more
than 60% in the patients with low dose of warfarin. The BMI and weight also showed a positive
correlation with warfarin dose. However, it was not statistically significant (p > 0.05). The
results of this study may be useful in defining of warfarin dose algorithms for Iranian patients.

Keywords

Main Subjects